Peter de Jonge
Auto-generated profile, based on publicly available information

Peter de Jonge

University of Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in JACC
Verified
Journal Article
Closed access
ARAnnelieke M. Roest
Annelieke M. Roest
EMElisabeth J. Martens
Elisabeth J. Martens
PJPeter de Jonge
Peter de Jonge
JDJohan Denollet
Johan Denollet

22 January 2018 in Depression and Anxiety
Verified
Journal Article
Closed access
PDF file
JAJordi Alonso
Jordi Alonso
ZLZhaorui Liu
Zhaorui Liu
SESara Evans-Lacko
Sara Evans-Lacko
ESEkaterina Sadikova
Ekaterina Sadikova
NSNancy Sampson
Nancy Sampson
TCthe WHO World Mental Health Survey Collaborators
the WHO World Mental Health Survey Collaborators

23 October 2012 in Molecular Psychiatry
Verified
Journal Article
Closed access
FLF Lamers
F Lamers
NVN Vogelzangs
N Vogelzangs
KMK R Merikangas
K R Merikangas
PJP de Jonge
P de Jonge
ABA T F Beekman
A T F Beekman
BPB W J H Penninx
B W J H Penninx

1 March 2019 in JAMA Psychiatry
Verified
Journal Article
Closed access
PDF file
OPOleguer Plana-Ripoll
Oleguer Plana-Ripoll
CPCarsten Bøcker Pedersen
Carsten Bøcker Pedersen
YHYan Holtz
Yan Holtz
MBMichael Eriksen Benros
Michael Eriksen Benros
SDSøren Dalsgaard
Søren Dalsgaard
JMJohn McGrath
John McGrath
Comorbidity, defined as the presence of 1 or more disorders in relation to an index disorder,1 has been the focus of a substantial body of research during the 5 decades since the term was introduced.2 In the mental health field, it is widely acknowledged that individuals treated for incident mental disorders are at increased risk of subsequently developing other mental disorders.3 Based on a survey of mental health among adolescents 13 to 17 years of age, Kessler et al4 reported that 27.9% of respondents met criteria for 2 or more disorders. Several community surveys have reported that, among respondents with at least 1 mental disorder, 45% to 54% have 1 or more additional lifetime diagnoses.3,5,6

1 February 2016 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
KSKate M. Scott
Kate M. Scott
CLCarmen Lim
Carmen Lim
AAAli Al-Hamzawi
Ali Al-Hamzawi
JAJordi Alonso
Jordi Alonso
RBRonny Bruffaerts
Ronny Bruffaerts
RKRonald C. Kessler
Ronald C. Kessler
Much evidence has accrued from record linkage and clinical studies attesting to the higher incidence of chronic physical conditions and associated earlier mortality among individuals with severe mental illness,1-3 as well as among those with common mental disorders.4-7 However, the findings of these studies are limited to those who receive treatment,1 so it is less clear whether mental disorders in the community (untreated and treated) might be linked with subsequent risk of chronic physical conditions. It also remains unclear as to how generalized these associations might be across a range of physical health outcomes. This information has important implications for mental health care and the primary prevention of chronic physical disease.

31 July 2017 in BMC Medicine
Verified
Journal Article
Open access
PDF file
DSDan J. Stein
Dan J. Stein
CLCarmen Lim
Carmen Lim
ARAnnelieke M. Roest
Annelieke M. Roest
PJPeter De Jonge
Peter De Jonge
SASergio Aguilar-Gaxiola
Sergio Aguilar-Gaxiola
KSKate M. Scott
Kate M. Scott
There is evidence that social anxiety disorder (SAD) is a prevalent and disabling disorder. However, most of the available data on the epidemiology of this condition originate from high income countries in the West. The World Mental Health (WMH) Survey Initiative provides an opportunity to investigate the prevalence, course, impairment, socio-demographic correlates, comorbidity, and treatment of this condition across a range of high, middle, and low income countries in different geographic regions of the world, and to address the question of whether differences in SAD merely reflect differences in threshold for diagnosis. Data from 28 community surveys in the WMH Survey Initiative, with 142,405 respondents, were analyzed. We assessed the 30-day, 12-month, and lifetime prevalence of SAD, age of onset, and severity of role impairment associated with SAD, across countries. In addition, we investigated socio-demographic correlates of SAD, comorbidity of SAD with other mental disorders, and treatment of SAD in the combined sample. Cross-tabulations were used to calculate prevalence, impairment, comorbidity, and treatment. Survival analysis was used to estimate age of onset, and logistic regression and survival analyses were used to examine socio-demographic correlates. SAD 30-day, 12-month, and lifetime prevalence estimates are 1.3, 2.4, and 4.0% across all countries. SAD prevalence rates are lowest in low/lower-middle income countries and in the African and Eastern Mediterranean regions, and highest in high income countries and in the Americas and the Western Pacific regions. Age of onset is early across the globe, and persistence is highest in upper-middle income countries, Africa, and the Eastern Mediterranean. There are some differences in domains of severe role impairment by country income level and geographic region, but there are no significant differences across different income level and geographic region in the proportion of respondents with any severe role impairment. Also, across countries SAD is associated with specific socio-demographic features (younger age, female gender, unmarried status, lower education, and lower income) and with similar patterns of comorbidity. Treatment rates for those with any impairment are lowest in low/lower-middle income countries and highest in high income countries. While differences in SAD prevalence across countries are apparent, we found a number of consistent patterns across the globe, including early age of onset, persistence, impairment in multiple domains, as well as characteristic socio-demographic correlates and associated psychiatric comorbidities. In addition, while there are some differences in the patterns of impairment associated with SAD across the globe, key similarities suggest that the threshold for diagnosis is similar regardless of country income levels or geographic location. Taken together, these cross-national data emphasize the international clinical and public health significance of SAD.